In Treatment of Type 2 diabetes mellitus Aloja 12.5 Tablet belongs to a group of medicines called DPP-4 inhibitors. It helps increase the amount of insulin your body produces after a meal and to stop your body from releasing too much glucose (sugar) into your blood. This way it lowers the blood glucose levels in your body. It is usually taken once a day. Lowering blood glucose levels is an essential part of managing diabetes. Controlling the blood glucose level helps prevent serious complications of diabetes such as kidney damage, blindness, and loss of limbs. Proper control of diabetes can also reduce the risk of heart disease and stroke. Taking this medicine regularly along with a proper program of diet and exercise will help you live a normal, healthy life. You should keep using it for as long as it is prescribed for long-term benefits.
It is unsafe to consume alcohol with Aloja 12.5 Tablet.
Aloja 12.5 Tablet is generally considered safe to use during pregnancy. Animal studies have shown low or no adverse effects to the developing baby; however, there are limited human studies.
Information regarding the use of Aloja 12.5 Tablet during breastfeeding is not available. Please consult your doctor.
It is not known whether Aloja 12.5 Tablet alters the ability to drive. Do not drive if you experience any symptoms that affect your ability to concentrate and react.
Aloja 12.5 Tablet should be used with caution in patients with kidney disease. Dose adjustment of Aloja 12.5 Tablet may be needed. Please consult your doctor.
Aloja 12.5 Tablet should be used with caution in patients with liver disease. Dose adjustment of Aloja 12.5 Tablet may be needed. Please consult your doctor.
If you miss a dose of Aloja 12.5 Tablet, take it as soon as possible. However, if it is almost time for your next dose, skip the missed dose and go back to your regular schedule. Do not double the dose.
FDC Ltd | B-8, MIDC Area, Waluj - 431 136, Dist. Aurangabad, Maharashtra
Marketer/Manufacturer: Abbott || ₹14.5/tablet (25% cheaper)
No customer reviews yet.
FDA approved prescribing information. Levocitrizine; 1995 [revised May 2007]. [Accessed 01 Apr. 2019] (online) Available from: Read More
European Medicne Agency. Revised assessment report: Ambroxol and bromhexine containing medicinal products. 2015. [Accessed 01 Apr. 2019] (online) Available from: Read More
ScienceDirect. Ambroxol. [Accessed 01 Apr. 2019] (online) Available from: Read More
Levocitrizine. Slough, Berkshire: UCB Pharma Limited; 2007 [revised 27 Mar. 2019]. [Accessed 01 Apr. 2019] (online) Available from: Read More